Jan 02, 2018 - The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S
Dec 29, 2017 - We take a look at a few Large Cap stocks, which have surpassed the S&P 500 index in 2017 due to upsides on both regulatory and pipeline fronts.
Dec 19, 2017 - Looking for income from the pharmaceutical industry? Start with these three companies.
Dec 18, 2017 - Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorisation of semaglutide for the treatment of adults with type II diabetes mellitus.
Dec 14, 2017 - Eli Lilly (LLY) issues financial guidance for 2018 and also reaffirms the previously issued 2017 projection as well as its long-term expectations.
Dec 11, 2017 - Investors in Europe remained focused on Brexit negotiations and the Senate's decision to approve a new tax Bill last week.
Dec 08, 2017 - FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
Dec 06, 2017 - The following slide deck was published by Novo Nordisk A/S in conjunction with this event.
Dec 06, 2017 - Novo Nordisk (NVO) announced that the FDA approved semaglutide, which is a once-weekly injection approved to improve glycaemic control in adults with type II diabetes mellitus.
Dec 05, 2017 - Sanofi's (SNY) head-to-head study comparing Toujeo long-acting insulin to Novo Nordisk's Tresiba long-acting insulin (insulin degludec) meets its objective.